Breaking News

Merck Launches Weight Management Business

By Kristin Brooks | December 20, 2013

To provide weight management interventions in the U.S.

Merck has launched a new business focused on providing comprehensive, evidence-based weight management interventions for employers, hospitals, medical groups, health plans, and patients. The business will provide weight management interventions that combine a structured diet, behavior coaching and monitoring and physical activity to achieve clinically meaningful weight loss to help reduce the risks of chronic illnesses, such as diabetes and cardiovascular disease.
 
A company has been created called HMR Weight Management Services Corp., which combines Merck’s capabilities and assets from Health Management Resources Corporation (HMR), a provider of medical weight management services. The new company will operate as a subsidiary of Merck.
 
“We’re excited to provide scalable weight management interventions based on approaches that have shown consistent results in clinical trials, and that have been effective in the battle against obesity,” said Len Tacconi, president of HMR Weight Management Services Corp.
 
The business welcomes all customers to its programs and services regardless of their use of any medicines or programs offered by Merck or any other company, according to a Merck statement.
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research